Treats hypertension. ANDA 215959, held by Granules India. Losartan Potassium.
As of Nov 21, 2026, ANDA 215959 (Losartan Potassium), held by Granules India, was first approved by FDA on Feb 23, 2023, with 1 approved supplement and 0 published complete response letters.
Losartan potassium tablet is an angiotensin II receptor blocker (ARB) indicated for:
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 23, 2023 | Original application | Approved | None posted |
| Losartan Potassium25MG · tablet;oral | Losartan Potassium | Rx |
| Losartan Potassium50MG · tablet;oral | Losartan Potassium | Rx |
| Losartan Potassium100MG · tablet;oral | Losartan Potassium | Rx |
| Oct 29, 2025 | Supplement 7Labeling · Standard review | Approved | None posted |
| Feb 23, 2023 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters